Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$110.32 USD

110.32
858,848

+0.39 (0.35%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $110.30 -0.02 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (185 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amicus (FOLD) Gets Approval in Europe for Pompe Disease Drug

by Zacks Equity Research

Amicus (FOLD) receives approval for Opfolda (miglustat) from the European Commission to treat the adult late-onset Pompe disease.

Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint

by Zacks Equity Research

Agios' (AGIO) mid-stage, label expansion study of mitapivat meets its primary endpoint. The data from the study supports AGIO's decision to proceed with the phase III portion of the investigation.

FibroGen (FGEN) Plunges on Failure of Late-Stage IPF Study

by Zacks Equity Research

FibroGen (FGEN) plummets on yet another pipeline setback. The phase III study, ZEPHYRUS-1, evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis fails to meet goals.

Bristol Myers (BMY) Heart Drug Camzyos Wins EC Approval

by Zacks Equity Research

Bristol Myers (BMY) receives EC approval for Camzyos for treating symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM) in adult patients.

NVS or LLY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NVS vs. LLY: Which Stock Is the Better Value Option?

Pfizer (PFE) Stock Down on Halting Development of Obesity Drug

by Zacks Equity Research

Shares of Pfizer's (PFE) fell 3.7% on Monday after management's decision to terminate the development of an experimental obesity pill following concerns over liver safety.

GSK's (GSK) Gonorrhoea Vaccine Gets FDA Fast Track Tag

by Zacks Equity Research

The FDA grants fast-track designation to GSK's investigational gonorrhoeae vaccine candidate. The grant enables GSK to seek expedited review for a potential FDA filing of the vaccine.

Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion

by Zacks Equity Research

Gilead's breast cancer drug Trodelvy gets positive CHMP opinion for a second indication in Europe.

AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval

by Zacks Equity Research

AbbVie (ABBV) receives a positive recommendation from the European Union's medicinal products committee for the approval of its migraine treatment candidate, atogepant.

Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data

by Zacks Equity Research

Novo Nordisk (NVO) announces encouraging new data from its late-stage ONWARDS 1 and 3 studies on once-weekly basal insulin icodec against once-daily comparators at 52 and 26 weeks, respectively.

Amylyx (AMLX) Down on Negative CHMP Opinion for ALS candidate

by Zacks Equity Research

Amylyx's (AMLX) shares plunge on getting a negative opinion from the Committee for Medicinal Products for Human Use for the marketing authorization of AMX0035, used to treat amyotrophic lateral sclerosis.

Pfizer's (PFE) Litfulo Receives FDA Nod for Alopecia Areata

by Zacks Equity Research

Pfizer's (PFE) Litfulo becomes the first kinase inhibitor approved for treating severe alopecia areata in adolescents, following FDA's approval.

Zacks.com featured highlights Toll Brothers, Walmart, Caterpillar, W.W. Grainger and Novartis

by Zacks Equity Research

Toll Brothers, Walmart, Caterpillar, W.W. Grainger and Novartis have been highlighted in this Screen of The Week article.

Gilead Sciences (GILD) Announces Positive HDV Treatment Data

by Zacks Equity Research

Gilead Sciences, Inc. (GILD) announces data on Hepcludex that reinforces the potential of bulevirtide as an effective and well-tolerated treatment for chronic HDV after 96 weeks.

Sarepta (SRPT) Gets FDA's Accelerated Nod for DMD Gene Therapy

by Zacks Equity Research

Following FDA???s approval, Sarepta's (SRPT) Elevidys becomes the first gene therapy for treating DMD.

Sweta Killa headshot

5 Dividend Growth Stocks to Buy for Gains in the Second Half

by Sweta Killa

Toll Brothers (TOL), Walmart (WMT), Caterpillar (CAT), W.W. Grainger (GWW) and Novartis (NVS) could be compelling picks heading into the second half of the year.

bluebird's (BLUE) Gene Therapy for SCD Gets Priority Review

by Zacks Equity Research

bluebird's (BLUE) gene therapy lovotibeglogene autotemcel gets Priority Review in the United States for sickle cell disease.

Lilly (LLY) Gets FDA Nod for Pediatric Use of Diabetes Drugs

by Zacks Equity Research

Following FDA's label expansion approval, Lilly's (LLY) Jardiance and Synjardy are the first SGLT2 inhibitors approved for use in children aged 10 years and older with type 2 diabetes.

FDA Expands Pfizer's (PFE) Talzenna Label in Prostate Cancer

by Zacks Equity Research

Following FDA's label-expansion approval, Pfizer's (PFE) Talzenna is the first PARP inhibitor approved in combination with existing standard of care for treating HRR gene-mutated mCRPC.

DICE Therapeutics (DICE) Up 37% on Buyout Offer from Eli Lilly

by Zacks Equity Research

DICE Therapeutics (DICE) is set to be acquired by pharma-giant Eli Lilly (LLY) in an all-cash transaction for $2.4 billion. The transaction will likely close by third-quarter 2023.

Arcellx (RCLX) Down on Hold for Lead Program CART-ddBCMA

by Zacks Equity Research

Arcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or refractory multiple myeloma has been put on hold by the FDA. The company's shares decline on the same.

AstraZeneca (AZN) May Reportedly Spin-Off its Chinese Business

by Zacks Equity Research

AstraZeneca (AZN) reportedly plans to spin-off its China business and list it separately in Hong Kong to protect itself from rising tensions between the United States and China.

Why Novartis (NVS) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Bristol Myers (BMY) Announces CAR T Cell Therapy Breyanzi Data

by Zacks Equity Research

Bristol Myers' (BMY) CAR T cell therapy Breyanzi (lisocabtagene maraleucel) shows deep and durable responses in relapsed or refractory follicular lymphoma and mantle cell lymphoma.